Recombinant RSV/hMPV Antibodies for Dual-Virus Neutralization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are no approved therapeutic or prophylactic options against human metapneumovirus (hMPV) infection, and existing strategies for respiratory syncytial virus (RSV) have faced challenges in disease enhancement and vaccine design, necessitating improved antibodies for both viruses.

Innovation Solution

Development of recombinant antibodies with specific heavy and light chain sequences, including complementarity determining regions (CDRs), that are cross-reactive to RSV and hMPV, along with methods for their production and administration to treat respiratory infections.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional RSV vaccine strategies are used, then immune response is generated, but disease enhancement occurs

Engineering Contradiction:

Improveimmune responseVSAvoiddisease enhancement

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the structural parameters of the F protein antigen used in vaccination. Specifically, it uses the prefusion conformation of the F protein (a specific structural state) rather than the postfusion form, and incorporates specific mutations (such as Pro287 to Thr287) to stabilize this conformation. This structural parameter change enables the generation of neutralizing antibodies without causing disease enhancement, thus resolving the contradiction between generating immune response and avoiding harmful effects.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If RSV-specific antibodies are developed, then RSV protection is achieved, but cross-protection against hMPV is lost

Engineering Contradiction:

ImproveRSV protectionVSAvoidcross-protection

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies universality by designing an antibody and antigen system that serves multiple functions: it provides protection against RSV while also conferring cross-protection against hMPV. The engineered anti-F protein antibodies (such as mAb 5-1) are capable of recognizing and neutralizing both RSV and hMPV viruses. Similarly, the prefusion F protein antigen can elicit antibodies that recognize epitopes conserved across both virus types, thus achieving multi-functional protection against related pneumoviruses.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250296987A1RSV/hmpv cross-reactive antibodies

Publication Date: 2025.09.25 VANDERBILT UNIV

AI summary

The present disclosure relates to cross-reactive RSV/hMPV antibodies, RSV/hMPV antibody compositions, and methods of use thereof.